GLP-1: To Cover, or Not to Cover?
The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, has greatly improved weight management by providing significant help with weight loss. However, their high costs and growing demand have led to a complex debate among employers about whether to cover them under group health plans. Efficacy and Rising Demand GLP-1 drugs are very effective for weight loss. Semaglutide, for example, can help people lose 15% to 20% of their body weight, making it a strong choice for treating obesity, and demand has surged. An estimated